Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined LDL-C, Lp(a), and hsCRP Assessment Predicts ASCVD in the Multiethnic HELIUS Cohort.

Journal of the American College of Cardiology·2026
Same author

The emerging role of coronary computed tomography for prevention of cardiovascular disease in asymptomatic individuals.

European journal of preventive cardiology·2026
Same author

The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention.

European journal of preventive cardiology·2026
Same author

Bridging the gap in prevention of first myocardial infarction.

European heart journal·2026
Same author

Reduced postprandial lipid accumulation in circulating monocytes by olezarsen attenuates pro-inflammatory changes in hypertriglyceridemic patients.

European heart journal open·2026
Same author

Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a).

JAMA cardiology·2026

Related Experiment Videos

ASCVD Risk Stratification Using Apolipoprotein B and the LDL-C to Total Cholesterol Ratio.

Bin Wang1, Nick S Nurmohamed2,3, Jordan M Kraaijenhof2

  • 1Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.

European Journal of Preventive Cardiology
|May 9, 2026
PubMed
Summary
This summary is machine-generated.

A dual-axis approach using Apolipoprotein B (ApoB) particle burden and LDL cholesterol/total cholesterol (LDL-C/TC) ratio better predicts atherosclerotic cardiovascular disease (ASCVD) risk than LDL-C alone. This method reveals hidden risks for improved ASCVD prevention.

Keywords:
ASCVD risk stratificationLDL-C/total cholesterol ratioapolipoprotein Bdual-axis lipid frameworkprimary prevention

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Preventive Cardiology

Background:

  • Low-density lipoprotein cholesterol (LDL-C) is a known cause of atherosclerotic cardiovascular disease (ASCVD).
  • Significant variation in ASCVD risk exists across the LDL-C spectrum.
  • Existing risk stratification may not fully capture individual susceptibility.

Purpose of the Study:

  • To evaluate a dual-axis model integrating Apolipoprotein B (ApoB) particle burden and LDL cholesterol/total cholesterol (LDL-C/TC) ratio for ASCVD risk.
  • To determine if this dual-axis structure offers superior risk prediction compared to traditional markers.
  • To identify distinct phenotypes based on ApoB and LDL-C/TC ratio for refined risk assessment.

Main Methods:

  • Analysis of six US adult cohorts without prior cardiovascular disease or lipid-lowering therapy.
  • Dichotomization of ApoB (90 mg/dL) and LDL-C/TC ratio (0.60) to define four risk phenotypes.
  • Incident ASCVD events assessed using multivariable Cox proportional hazards models.

Main Results:

  • ApoB and LDL-C/TC ratio showed stronger associations with ASCVD risk than LDL-C levels.
  • The dual-elevated phenotype exhibited the highest ASCVD incidence (HR 1.67).
  • Discordant phenotypes revealed varying risk levels, with high ApoB/low ratio showing borderline associations.

Conclusions:

  • A dual-axis framework of ApoB particle burden and LDL-C/TC ratio provides a more coherent explanation of LDL-related atherogenic risk.
  • This approach identifies composition-driven vulnerabilities missed by ApoB alone or standard risk scores.
  • Routine LDL-C/TC ratio interpretation combined with selective ApoB testing can enhance ASCVD risk stratification.